pagibaximab

Pagibaximab is a chimeric (mouse/human) monoclonal antibody developed for the prevention of staphylococcal sepsis in infants with low birth weight. It specifically targets lipoteichoic acid, a major cell wall component of gram-positive bacteria such as *Staphylococcus epidermidis* and *Staphylococcus aureus*. The drug acts by promoting opsonophagocytic killing, leading to bacterial clearance. Pagibaximab was shown to be effective in preclinical studies and animal models, as well as safe and well tolerated in phase 1/2 clinical trials involving very low birth weight neonates. The serum half-life is approximately 20 days, which supports its use for infection prevention during hospitalization of premature infants[1][5][6][8]. Development was led by Biosynexus and Applied Molecular Evolution; GlaxoSmithKline Biologicals was also involved in co-development[4][6]. Despite promising early results, development for staphylococcal infections has been discontinued[4].

Other names

pagibaximab